Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entereg User Fee Date Pushed Back To May

This article was originally published in The Pink Sheet Daily

Executive Summary

Extension allows FDA to review revised RiskMAP recently submitted by Adolor for the postoperative ileus treatment.

You may also be interested in...



FDA Needs More Time To Review GSK/Adolor’s Entereg

Adolor tells investors that FDA will not act on the postoperative ileus treatment in time to meet the May 10 PDUFA date.

FDA Needs More Time To Review GSK/Adolor’s Entereg

Adolor tells investors that FDA will not act on the postoperative ileus treatment in time to meet the May 10 PDUFA date.

Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too

Compound helps bowel function in dying patients on opioids.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel